The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 55 results
June 2022
-
Media Release
Novartis Pro Portal reimagines knowledge exchange in patient care, with seamless collaboration between the pharmaceutical industry and physicians
The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice. Dorval… -
Media Release
Health Canada approves PrTabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer Dorval, Quebec, June 8,…
October 2021
-
Media Release
Novartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)
In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining… -
Media Release
Novartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)
Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is… -
Media Release
New campaign highlights urgent need for action to address the growing crisis of preventable vision loss and blindness
This World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch “All Eyes on You”, a campaign urging Canadians to lend their… -
Media Release
Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)
Dorval, Quebec, October 13, 2021 — Novartis Pharmaceuticals Canada Inc. today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent… -
Media Release
Novartis Pharmaceuticals Canada Inc. announces digital innovation partnership in multiple sclerosis with Innodem Neurosciences
Clinical trial will study new technology that tracks eye movement to assist diagnosis and monitor disease progression Dorval, Quebec, October 5, 2021 — Novartis Pharmaceuticals Canada Inc. (…
April 2021
-
Media Release
Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still’s disease
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still’s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening… -
Media Release
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)i
Expansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell…